The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. (Q42805035)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Feihl S

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Mugler C

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Grundler R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

von Bubnoff N

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Lordick F

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Peschel C

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Duyster J

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

1 reference

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

650-657

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404151

16 January 2020

exact match

0 references

cites work

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Structured treatment interruption in patients infected with HIV: a new approach to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Clinical resistance to imatinib: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

A screen to identify drug resistant variants to target-directed anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

An activating mutation in the ATP binding site of the ABL kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

Acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

7 January 2021

inferred from DOI database lookup

Highly efficient green fluorescent protein-based kinase substrates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

7 January 2021

inferred from DOI database lookup

Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404151

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.LEU.2404151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16482207%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

16 January 2020

1038692361

0 references

Fatcat ID

release_h2254eq7evhe3ajj7fpoqzt4mu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2254eq7evhe3ajj7fpoqzt4mu

24 November 2022

mapped directly with Wikidata item

1 reference